Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales

被引:182
作者
El-Kenawi, Asmaa E. [1 ]
El-Remessy, Azza B. [2 ,3 ,4 ]
机构
[1] Mansoura Univ, Fac Pharm, Dept Pharmacol & Toxicol, Mansoura, Egypt
[2] Univ Georgia, Ctr Pharm & Expt Therapeut, Augusta, GA 30912 USA
[3] Georgia Regents Univ, Dept Pharmacol & Toxicol, Augusta, GA USA
[4] Charlie Norwood VA Med Ctr, Augusta, GA USA
关键词
angiogenesis inhibitors; cancer therapy; tumour micro-environment; ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; RANDOMIZED PHASE-II; COOPERATIVE-ONCOLOGY-GROUP; FACTOR-KAPPA-B; TRIPLE ANGIOKINASE INHIBITOR; REFRACTORY PROSTATE-CANCER; LOW-DOSE CYCLOPHOSPHAMIDE; CELL-ADHESION MOLECULES; ADVANCED GASTRIC-CANCER;
D O I
10.1111/bph.12344
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Angiogenesis, a process of new blood vessel formation, is a prerequisite for tumour growth to supply the proliferating tumour with oxygen and nutrients. The angiogenic process may contribute to tumour progression, invasion and metastasis, and is generally accepted as an indicator of tumour prognosis. Therefore, targeting tumour angiogenesis has become of high clinical relevance. The current review aimed to highlight mechanistic details of anti-angiogenic therapies and how they relate to classification and treatment rationales. Angiogenesis inhibitors are classified into either direct inhibitors that target endothelial cells in the growing vasculature or indirect inhibitors that prevent the expression or block the activity of angiogenesis inducers. The latter class extends to include targeted therapy against oncogenes, conventional chemotherapeutic agents and drugs targeting other cells of the tumour micro-environment. Angiogenesis inhibitors may be used as either monotherapy or in combination with other anticancer drugs. In this context, many preclinical and clinical studies revealed higher therapeutic effectiveness of the combined treatments compared with individual treatments. The proper understanding of synergistic treatment modalities of angiogenesis inhibitors as well as their wide range of cellular targets could provide effective tools for future therapies of many types of cancer.
引用
收藏
页码:712 / 729
页数:18
相关论文
共 243 条
  • [1] Inhibition of αvβ3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy
    Abdollahi, A
    Griggs, DW
    Zieher, H
    Roth, A
    Lipson, KE
    Saffrich, R
    Gröne, HJ
    Hallahan, DE
    Reisfeld, RA
    Debus, J
    Niethammerl, AG
    Huber, PE
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (17) : 6270 - 6279
  • [2] Endostatin's antiangiogenic signaling network
    Abdollahi, A
    Hahnfeldt, P
    Maercker, C
    Gröne, HJ
    Debus, J
    Ansorge, W
    Folkman, J
    Hlatky, L
    Huber, PE
    [J]. MOLECULAR CELL, 2004, 13 (05) : 649 - 663
  • [3] Tumor inflammatory angiogenesis and its chemoprevention
    Albini, A
    Tosetti, F
    Benelli, R
    Noonan, DM
    [J]. CANCER RESEARCH, 2005, 65 (23) : 10637 - 10641
  • [4] Diabetic Retinopathy: Current Management and Experimental Therapeutic Targets
    Ali, Tayyeba K.
    El-Remessy, Azza B.
    [J]. PHARMACOTHERAPY, 2009, 29 (02): : 182 - 192
  • [5] Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition
    Allen, Elizabeth
    Walters, Ian B.
    Hanahan, Douglas
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (16) : 5299 - 5310
  • [6] Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
    Angevin, Eric
    Lopez-Martin, Jose A.
    Lin, Chia-Chi
    Gschwend, Juergen E.
    Harzstark, Andrea
    Castellano, Daniel
    Soria, Jean-Charles
    Sen, Paramita
    Chang, Julie
    Shi, Michael
    Kay, Andrea
    Escudier, Bernard
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (05) : 1257 - 1268
  • [7] [Anonymous], PLOS ONE
  • [8] [Anonymous], COLD SPRING HARB PER
  • [9] Aplin AE, 1998, PHARMACOL REV, V50, P197
  • [10] HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α
    Arany, Zoltan
    Foo, Shi-Yin
    Ma, Yanhong
    Ruas, Jorge L.
    Bommi-Reddy, Archana
    Girnun, Geoffrey
    Cooper, Marcus
    Laznik, Dina
    Chinsomboon, Jessica
    Rangwala, Shamina M.
    Baek, Kwan Hyuck
    Rosenzweig, Anthony
    Spiegelman, Bruce M.
    [J]. NATURE, 2008, 451 (7181) : 1008 - U8